Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Cubist, Morphosys and Takeda.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

May 22, 2015
Heptares Scientist Wins Outstanding Young Chemist Award
Feb 23, 2015

Sosei Acquires Heptares Therapeutics for up to USD 400 million


Jun 8-9, 2015
16th Drug Discovery & 3rd Discovery Chemistry & Drug Design Congress
Berlin, Germany

Presenting: Jon Mason

Jun 15-18, 2015
BIO 2015 International Convention
Philadelphia, PA, USA
Attending: Dan Grau

© 2012-2015 Heptares Therapeutics